新型脂阿拉伯甘露聚糖即时结核检测在HIV感染者中的诊断准确性研究
本研究评估了Fujifilm SILVAMP TB LAM(FujiLAM)对比AlereLAM在HIV住院患者中诊断结核病的准确性。FujiLAM可能改善HIV住院患者的快速即时结核诊断。
要点
- FujiLAM在HIV住院患者中诊断结核的敏感性显著优于AlereLAM。
- FujiLAM保持较高特异性,但略低于AlereLAM。
- FujiLAM有望变革HIV住院患者的快速即时结核诊断。
核心结论
- 与AlereLAM相比,FujiLAM在保持特异性的同时提供了更优的诊断敏感性。
- FujiLAM可能变革HIV住院患者的快速即时结核诊断。
- FujiLAM在预期使用场景中的适用性需前瞻性评估。
研究设计与样本
- 诊断准确性研究,评估来自FIND标本库和开普敦大学生物库的尿样。
- 样本来自南非两家医院的三项独立前瞻性队列研究中的HIV住院患者(年龄≥18岁)。
- 共评估968例HIV住院患者的尿样。
- 尿样同时使用FujiLAM和AlereLAM检测,检测与报告均对另一检测结果设盲。
- 主要目标为对比FujiLAM与AlereLAM在微生物学和复合参考标准下的诊断准确性。
主要发现
- 微生物学确诊结核的患病率为62%,中位CD4计数为86 cells/μL。
临床怎么用
- 对于HIV住院患者,FujiLAM可作为比AlereLAM更敏感的即时结核检测选择。
- FujiLAM的高敏感性有助于早期诊断结核,可能减少结核相关死亡。
- FujiLAM在预期使用场景中的适用性需前瞻性评估。
局限性
- 研究使用生物库冻存尿样,可能不完全反映新鲜样本的检测性能。
- 研究仅纳入南非两家医院的HIV住院患者,外推性有限。
- FujiLAM在预期使用场景中的适用性需前瞻性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most tuberculosis-related deaths in people with HIV could be prevented with earlier diagnosis and treatment. The only commercially available tuberculosis point-of-care test (Alere Determine TB LAM Ag [AlereLAM]) has suboptimal sensitivity, which restricts its use in clinical practice. The novel Fujifilm SILVAMP TB LAM (FujiLAM) assay has been developed to improve the sensitivity of AlereLAM. We assessed the diagnostic accuracy of the FujiLAM assay for the detection of tuberculosis in hospital inpatients with HIV compared with the AlereLAM assay. METHODS: For this diagnostic accuracy study, we assessed biobanked urine samples obtained from the FIND Specimen Bank and the University of Cape Town Biobank, which had been collected from hospital inpatients (aged ≥18 years) with HIV during three independent prospective cohort studies done at two South African hospitals. Urine samples were tested using FujiLAM and AlereLAM assays. The conduct and reporting of each test was done blind to other test results. The primary objective was to assess the diagnostic accuracy of FujiLAM compared with AlereLAM, against microbiological and composite reference standards (including clinical diagnoses). FINDINGS: Between April 18, 2018, and May 3, 2018, urine samples from 968 hospital inpatients with HIV were evaluated. The prevalence of microbiologically-confirmed tuberculosis was 62% and the median CD4 count was 86 cells per μL. Using the microbiological reference standard, the estimated sensitivity of FujiLAM was 70·4% (95% CI 53·0 to 83·1) compared with 42·3% (31·7 to 51·8) for AlereLAM (difference 28·1%) and the estimated specificity of FujiLAM was 90·8% (86·0 to 94·4) and 95·0% (87·7-98·8) for AlereLAM (difference -4·2%). Against the composite reference standard, the specificity of both assays was higher (95·7% [92·0 to 98·0] for FujiLAM vs 98·2% [95·7 to 99·6] for AlereLAM; difference -2·5%), but the sensitivity of both assays was lower (64·9% [50·1 to 76·7] for FujiLAM vs 38·2% [28·1 to 47·3] for AlereLAM; difference 26·7%). INTERPRETATION: In comparison to AlereLAM, FujiLAM offers superior diagnostic sensitivity, while maintaining specificity, and could transform rapid point-of-care tuberculosis diagnosis for hospital inpatients with HIV. The applicability of FujiLAM for settings of intended use requires prospective assessment. FUNDING: Global Health Innovative Technology Fund, UK Department for International Development, Dutch Ministry of Foreign Affairs, Bill & Melinda Gates Foundation, German Federal Ministry of Education and Research, Australian Department of Foreign Affairs and Trade, Wellcome Trust, Department of Science and Technology and National Research Foundation of South Africa, and South African Medical Research Council.
引用
- Broger T, Sossen B, du Toit E, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2019. PMID: 31155318. doi:10.1016/S1473-3099(19)30001-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。